TAKEDA PHARMA
TAKEDA PHARMA operates in Diversified Metals & Mining.
TAKEDA PHARMA (TKD) - Total Liabilities
Latest total liabilities as of September 2024: €7.65 Trillion EUR
Based on the latest financial reports, TAKEDA PHARMA (TKD) has total liabilities worth €7.65 Trillion EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TAKEDA PHARMA - Total Liabilities Trend (2017–2024)
This chart illustrates how TAKEDA PHARMA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TAKEDA PHARMA Competitors by Total Liabilities
The table below lists competitors of TAKEDA PHARMA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Österreichische Post AG
STU:O3P
|
Germany | €5.28 Billion |
|
AALBERTS IND (AACA.SG)
STU:AACA
|
Germany | €1.62 Billion |
|
Tri Continental Closed Fund
NYSE:TY
|
USA | $1.92 Million |
|
Portsmouth Square Inc
PINK:PRSI
|
USA | $172.61 Million |
|
STAND MOTOR PRODUCT
BE:SRU
|
Germany | €697.10 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down TAKEDA PHARMA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TAKEDA PHARMA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TAKEDA PHARMA (2017–2024)
The table below shows the annual total liabilities of TAKEDA PHARMA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | €7.83 Trillion | +3.05% |
| 2023-03-31 | €7.60 Trillion | +1.45% |
| 2022-03-31 | €7.49 Trillion | -3.11% |
| 2021-03-31 | €7.74 Trillion | -4.43% |
| 2020-03-31 | €8.09 Trillion | -7.06% |
| 2019-03-31 | €8.71 Trillion | +316.87% |
| 2018-03-31 | €2.09 Trillion | -13.20% |
| 2017-03-31 | €2.41 Trillion | -- |